Biofourmis, a Boston, MA-based developer of digital therapeutics for personalized predictive care, completed a $100m Series C financing.
The round was led by SoftBank Vision Fund with participation from existing investors Openspace Ventures, MassMutual Ventures, Sequoia Capital and EDBI.
The company intends to use the funds for developing, validating and commercializing several released and unreleased digital therapeutics solutions across cardiology, respiratory, oncology and pain, with a focus on the United States and key Asian markets, including Asia Pacific, China and Japan.
Led by CEO Kuldeep Singh Rajput, Biofourmis discovers, develops and delivers clinically validated software-based therapeutics. The company has built Biovitals®, a personalized AI-powered health analytics platform that predicts clinical exacerbation in advance of a critical event, which is the foundation of its digital therapeutics product pipeline across multiple therapeutic areas—including heart failure, oncology, infectious disease (i.e., COVID-19), chronic pain, acute coronary syndrome and COPD.
In May 2019, Biofourmis closed its $35 million Series B round. Since then, the company has increased its revenue through new partnerships and growth with seven pharmaceutical companies and 10 health systems globally. Biofourmis also made major acquisitions, including wearable biosensor leader Biovotion and Takeda Pharmaceuticals’ oncology-focused digital therapeutics company Gaido Health.